Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer.
Jodi M CarterMei-Yin C PolleyRoberto A Leon-FerreJason P SinnwellKevin J ThompsonXue WangYaohua MaDavid ZahriehJennifer M KachergusMalvika SolankiJudy C BougheyMinetta C LiuJames N IngleKrishna R KalariFergus J CouchE Aubrey ThompsonMatthew P GoetzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
In this early-stage TNBC cohort, nearly 50% were PD-L1+ (SP142 companion assay) while 16% were PD-L1+ with the 22C3 companion assay. PD-L1+ TNBC had specific myeloid-derived and lymphoid features. Spatially defined PD-L1+ TIME were enriched in several clinically actionable immune proteins. These data may inform future studies on combinatorial immunotherapies for patients with PD-L1+ TNBC.See related commentary by Symmans, p. 5446.